ArticleMarine life science & technology2026
Design and construction of cuttlefish ink derived melanin complexed microneedles for microenvironment regulation to improve vitiligo treatment.
Article in Marine life science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is an autoimmune disorder marked by melanocyte destruction and epidermal depigmentation, primarily driven by inflammatory and oxidative stress within the affected skin lesions. Consequently, there is an urgent need for therapeutic strategies focused on protecting melanocytes and replenishing melanin for effective vitiligo management. In this study, a novel microneedle-based therapeutic platform (C/D/E@MN) was fabricated that was composed of cuttlefish ink nanoparticles (CINPs) for melanin supplementation, dipotassium glycyrrhizinate (DPG) for inflammation regulation, and skin-derived exosomes (EXO) to promote melanocyte proliferation. In addition, microneedles with varying dissolution profiles (swellable, slow-dissolving, and fast-dissolving) were designed and evaluated their performance to optimize therapeutic efficacy. In vitro results demonstrated that fast-dissolving microneedles (FDMN) significantly reduced cellular reactive oxygen species (ROS) and the secretion of vitiligo-related inflammatory cytokines and chemokines, such as IL-8, CXCL-16, and HMGB-1. Upon a vitiligo mice model, C/D/E@FDMN treatment group generated a significant increase in skin melanin content and a 15.5% reduction of whitening degree. The microneedles protected melanocytes and promoted lesion repigmentation through synergistic antioxidant, anti-inflammatory and cyto-proliferative mechanisms, offering a promising strategy for improved vitiligo therapy. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s42995-025-00318-5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.